JonesResearch initiated coverage of Beam Therapeutics with a Hold rating and no price target. Beam is one of the lead companies with a base editing platform and its lead indication is in “crowded” sickle cell disease, the analyst tells investors in a research note. The firm awaits clinical data to justify the company’s current implied valuation.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BEAM:
- Intellia Therapeutics price target lowered to $64 from $80 at Stifel
- Krystal Biotech price target raised to $220 from $204 at Stifel
- Beam Therapeutics price target raised to $69 from $66 at Stifel
- Beam Therapeutics price target lowered to $31 from $33 at Barclays
- Beam Therapeutics reports Q2 EPS ($1.11), consensus ($1.13)